

UNITED STATES PATENT AND TRADEMARK OFFICE

()

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/666,833	09/19/2003	Andrew H. Segal	11111/2003D	6845
29933	7590 02/17/2005		EXAMINER	
PALMER & DODGE, LLP		LE, EMILY M		
KATHLEEN M. WILLIAMS 111 HUNTINGTON AVENUE			ART UNIT	PAPER NUMBER
BOSTON, MA 02199			1648	

DATE MAILED: 02/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/666,833	SEGAL ET AL.	,			
		Examiner	Art Unit				
		Emily Le	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE I - Exter after - If the - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REMAILING DATE OF THIS COMMUNICATION asions of time may be available under the provisions of 37 CF SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, to period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by steply received by the Office later than three months after the read patent term adjustment. See 37 CFR 1.704(b).	ON. R 1.136(a). In no event, howev n. a reply within the statutory minin eriod will apply and will expire SI tatute, cause the application to I	er, may a reply be timely filed num of thirty (30) days will be considered time IX (6) MONTHS from the mailing date of this become ABANDONED (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on 1	19 September 2003.					
2a) <u></u>	This action is FINAL . 2b)⊠	This action is non-final					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
5) 6) 7)	Claim(s) <u>1-13</u> is/are pending in the applica 4a) Of the above claim(s) is/are with Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-13</u> are subject to restriction and	ndrawn from considera					
Applicati	on Papers						
10)	The specification is objected to by the Exar The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the co The oath or declaration is objected to by the	accepted or b) objee the drawing(s) be held in the orrection is required if the	n abeyance. See 37 CFR 1.85(a). drawing(s) is objected to. See 37 C				
Priority u	ınder 35 U.S.C. § 119						
12) <u>□</u> a)l	Acknowledgment is made of a claim for for All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the application from the International Busee the attached detailed Office action for a	nents have been receivenents have been receivenents have been receiverity documents have 17.2(a	ved. ved in Application No ve been received in this Nationa a)).	ıl Stage			
2) Notice 3) Information	t(s) se of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948 mation Disclosure Statement(s) (PTO-1449 or PTO/SI r No(s)/Mail Date	B/08) F □ N	nterview Summary (PTO-413) Paper No(s)/Mail Date Notice of Informal Patent Application (PT Other:	ГО-152)			

Application/Control Number: 10/666,833 Page 2

Art Unit: 1648

DETAILED ACTION

Claims Status

1. Claims 1-13 are pending.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121: in the instant, claims 1-13 are directed to a plurality of distinct vaccine compositions. Applicant is required under 35 U.S.C. 121 to specify a specific composition for examination. To do so, Applicant is required to specify a specific fusion polypeptide, and a specific antigen bearing target that is included in the vaccine composition. In specifying a specific fusion protein, Applicant must specify a specific ligand (cytokine receptor, CD154--a ligand for CD40, a ligand for adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein, a ligand for a T cell costimulatory molecule, a ligand for a counterreceptor for a T cell costimulatory molecule, a ligand for an opsonin receptor), and an antigen bearing target (a tumor cell, a virus, bacterial cell, fungal cell, a cell of a parasite, a mammalian cell, an insect cell, a polypeptide free of other cell-derived material). If Applicant elects a cytokine receptor, Applicant is required to specify a specific cytokine (GM-CSF, an interleukin, a chemokine, an interferon, a TNF-alpha ligand a flt-3 ligand).
- 3. The inventions are distinct, each from the other because of the following reasons: All of the above listed entities are patentably distinct from one another. None of the entities share a significant structural similarity among one another. A

Application/Control Number: 10/666,833

Art Unit: 1648

search for one specific vaccine composition is not required for another specific vaccine composition.

Page 3

- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Le whose telephone number is (571) 272 0903. The examiner can normally be reached on Monday Friday, 8 am 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on (571) 272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/666,833

Art Unit: 1648

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jeffrey S. Parkin, Ph.D. Primary Patent Examiner Art Unit 1648

Chuly In